When was Phylo founded?

Phylo was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is Phylo located?

Phylo is headquartered in Boston, United States.

Who is the current CEO of Phylo?

Kexin Huang of Phylo. They have also founded 1 company.

How many employees does Phylo have?

As of May 31, 2026, the latest employee count at Phylo is 12.

Is Phylo a funded company?

Phylo is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Feb 09, 2026.

When was the latest funding round of Phylo?

Phylo's latest funding was a $***** Seed round on Feb 09, 2026, with participation from 5 investors.

Where does Phylo rank among its competitors?

Phylo ranks 33rd amongst 174 active competitors, of which 69 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of Phylo?

Phylo's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

Phylo - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of collaborative agents designed for biologists to accelerate discoveries. The agents are designed to help biologists make discoveries faster. It provides a unified workspace where biologists collaborate with agents to get more done. The agents ask clarifying questions, plan alongside the user, and iterate together. It integrates natively with the ecosystem of biomedical research.

Website: phylo.bio
Social
Email ID: *****@phylo.bio
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Boston, United States

Stage

Seed

Total Funding

$13.5M in 1 round

Latest Funding Round

Seed, Feb 09, 2026, $*****

Investors

Andreessen Horowitz & 4 more

Ranked

33^rd among 174 active competitors

Employee Count

12 as on May 31, 2026

Similar Companies

Schrodinger & 203 more

View Phylo's full profile

Phylo has raised a total funding of $13.5M over 1 round. Its latest funding round was a Seed round on Feb 09, 2026 for $*****. 5 investors participated in its latest round. Phylo has 5 institutional investors.

Here is the list of recent funding rounds of Phylo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 09, 2026	3846402	Seed	9203817	7820245	6265923	3135156

Access funding benchmarks and valuations. Sign up today!

View details of Phylo's funding rounds and investors

The founders of Phylo are Yuanhao Qu and Kexin Huang. Kexin Huang is the CEO of Phylo.

Here are the details of Phylo's key team members:

Yuanhao Qu: Co-Founder & President of Phylo.
Kexin Huang: Co-Founder & CEO of Phylo.

View details of Phylo's Founder profiles and Board Members

Phylo's employee count trend

Phylo has 12 employees as of May 26. Here is Phylo's employee count trend over the years:

Uncover Phylo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Phylo include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of Phylo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	67/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, Temasek & 5 others	64/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
7th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	Index Ventures, EBRD & 14 others	63/100
8th	Gero 2015, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	63/100
9th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
10th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Qiming Venture Partners & 4 others	62/100
33rd	Phylo 2020, Boston (United States), Seed	Developer of collaborative agents designed for biologists to accelerate discoveries	$13.5M	Zetta Venture Partners, Andreessen Horowitz ... & 3 others	49/100